Supernus Pharmaceuticals (SUPN) EBT Margin (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of EBT Margin data on file, last reported at 0.9% in Q4 2025.

• EBT Margin for Q4 2025 came in at 0.9%, down 1605.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 6.82% (down 2161.0% YoY), and the FY2025 annual result was 6.82%, down 2161.0% from the prior year.
• EBT Margin grew to 0.9% in Q4 2025 per SUPN's latest filing, from 30.17% in the prior quarter.
• Over five years, EBT Margin peaked at 25.58% in Q3 2024 and troughed at 30.17% in Q3 2025.
• A 5-year average of 6.01% and a median of 6.54% in 2023 frame the typical range for EBT Margin.
• The sharpest annual moves came in 2024 and 2025: EBT Margin jumped 2826 bps in 2024, then tumbled 5575 bps in 2025.
• A 5-year view of EBT Margin shows it stood at 1.29% in 2021, then soared by 1529 bps to 21.0% in 2022, then tumbled by 97 bps to 0.6% in 2023, then surged by 2414 bps to 15.15% in 2024, then plunged by 106 bps to 0.9% in 2025.
• Business Quant data shows SUPN's EBT Margin at 0.9% in Q4 2025, 30.17% in Q3 2025, and 10.07% in Q2 2025.